Nordisk Pharma ApS: Financial statements 2024
CVR: 42852287
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Nordisk Pharma ApS (CVR 42852287) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 552,864 and a net result of DKK 425,521 compared with DKK 262,984 the year before. That is an increase of 66.6% compared with the year before. Equity in the 2024 report amounted to DKK 1,009,504. The solvency ratio was 77.2%.
- Gross Profit
- DKK 552,864
- Profit/Loss
- DKK 425,521
- Equity
- DKK 1,009,504
- Total Assets
- DKK 1,307,696
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 553 t. | 426 t. | 1 mio. | 0 |
| 2023 | - | 332 t. | 263 t. | 584 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Nordisk Pharma ApS has published its annual report for 2023. Gross profit came to DKK 331,910, and the net result was DKK 262,984.
About Nordisk Pharma ApS
Nordisk Pharma ApS is a Danish company of the type Anpartsselskab based in Vallensbæk, founded in 2021. The company is registered under the industry Fremstilling af medicinske og dentale instrumenter samt udstyr hertil. The management consists of Sayed Edris Sadat and Sanad Emad Hussein Al Bidany. The company is owned by Nordisk Pharma Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 365,248 and a net result of DKK 207,225 compared with DKK 425,521 the year before. Equity in the 2025 report amounted to DKK 1,216,729.